Jeffrey Alan Bubis
21 works · 594 citations · h-index 8
Top works
- Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
- Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).
- A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure
- A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure
- Docetaxel in the Treatment of Esophageal Cancer
- Prevalence of paroxysmal nocturnal hemoglobinuria (PNH) cells in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA), or other bone marrow failure (BMF) syndromes: Interim results from the EXPLORE trial
- TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer
- Trimodality Therapy for Stage II–III Carcinoma of the Esophagus: A Dose-Ranging Study of Concurrent Capecitabine, Docetaxel, and Thoracic Radiotherapy
- Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC)
- Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes.
- First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel.
- Subcutaneous Administration of Alemtuzumab: A Single Institution Experience.
- Docetaxel (DTX) and carboplatin (CP) followed by a dose-ranging study of oral capecitabine, weekly DTX, concomitant radiotherapy and surgery for the treatment of patients with stage II-III carcinoma of the esophagus
- DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.
- Chemotherapeutic Treatment Issues in the Elderly
- Synergistic Effects of Bortezomib with Low Dose Melphalan Against Human AML Cells.
- Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). [2011 ASCO poster]
- Spontaneous Subdural Hematomas as Initial Presentation of Acquired Coagulopathy: A Case Report
- Trimodality therapy for stage II-III carcinoma of the esophagus: A dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.